Isolation and identification of major metabolites of rifalazil in mouse and human.

1. Three metabolites of rifalazil have been isolated from dog urine and identified as 25-deacetyl-rifalazil, 30-hydroxy-rifalazil and 25-deacetyl-30-hydroxy-rifalazil. In the current study major metabolites of rifalazil in mouse and human were isolated and identified, and their antimicrobial activities determined. 2. Urinary excretion of rifalazil and its metabolites in six mouse strains, CD-1 (ICR), BALB/c, C57BL/6, C3H/He, DBA/2 and CBA/J, was examined. Two major metabolites were detected in mouse urine obtained after several oral doses, and the proportion of rifalazil metabolites against total urinary excretion varied over a 2-fold range (4.8-8.7%) in the different mouse strains. 3. One of two major metabolites in mouse urine was 25-deacetyl-rifalazil and the other was unknown: it was isolated from mouse urine and identified by ms and 1H- and 13C-nmr as 32-hydroxy-rifalazil. 4. In human, two major metabolites of rifalazil were detected in urine obtained after administration of a single oral dose. These metabolites were also produced by incubation of rifalazil with pooled human liver microsomes, and identified by lc/ms and lc/ms/ms as 25-deacetyl-rifalazil and 32-hydroxy-rifalazil. 5. The antimicrobial activities of 32-hydroxy-rifalazil against gram-positive bacteria and mycobacteria were similar with those of the parent compound.

[1]  K. Fujii,et al.  Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs , 1996, Antimicrobial agents and chemotherapy.

[2]  J. Musser,et al.  Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations , 1996, Antimicrobial agents and chemotherapy.

[3]  L. Heifets,et al.  Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages , 1996, Antimicrobial agents and chemotherapy.

[4]  K. Suzuki,et al.  In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis , 1996, Antimicrobial agents and chemotherapy.

[5]  K. Fujii,et al.  In vitro metabolism of a rifamycin derivative by animal and human liver microsomes, whole blood and expressed human CYP3A isoform. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[6]  H. Tomioka,et al.  Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice. , 1995, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[7]  M. Cynamon,et al.  Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model , 1994, Antimicrobial Agents and Chemotherapy.

[8]  L. Bermudez,et al.  Activities of the benzoxazinorifamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophages , 1994, Antimicrobial Agents and Chemotherapy.

[9]  S. Miyazaki,et al.  In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives , 1994, Antimicrobial Agents and Chemotherapy.

[10]  T. Ohashi,et al.  High-performance liquid chromatographic determination of 3'-hydroxy-5'-(4-isobutyl-1-piperazinyl)benzoxazinorifamycin (KRM-1648) and its deacetyl metabolite in plasma, whole blood, urine and tissue samples in rats. , 1994, Journal of chromatography. B, Biomedical applications.

[11]  K. Watanabe,et al.  Synthesis and biological activity of 3'-hydroxy-5'-aminobenzoxazinorifamycin derivatives. , 1993, Chemical & pharmaceutical bulletin.

[12]  H. Tomioka,et al.  In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex, determined by the radiometric method , 1993, Antimicrobial Agents and Chemotherapy.